Understanding HER2-low and HER2-ultralow classification in mBC

In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.

The experts explore:

• Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
• The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
• When and why to perform re-biopsy to detect changes in HER2 expression over time
• Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis

Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.

Clinical takeaways

• DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
• Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
• Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
• T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment

This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/

X: https://x.com/BreastCaConnect

This content is intended for healthcare professionals only.

This programme is supported by an Independent Education Grant from AstraZeneca.

This podcast is developed by cor2ed.com

Published December 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

In this podcast, Medical Oncologist, Dr Aman Chauhan and Neuroendocrine Patient Advocate, Susan Meckler-Plummer, discuss extrapulmonary high-grade neuroendocrine carcinomas (EP-NECs), a rare, aggressive, and often misunderstood subset of neuroendocrine cancers.

They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.

Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease.

Key clinical takeaways:

• Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments

• While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise

• Accessing a support network can provide emotional reinforcement and information for patients and their care partners

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0

Or watch on YouTube: https://youtu.be/nfng2s3jSw8

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X:https://x.com/net_connectinfo

This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com

Published in November 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

How are advances in radioligand therapy shaping the treatment of neuroendocrine tumours, and what does recent trial evidence tell us? What are the key considerations for patient selection, sequencing, and safety?

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs.

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy.

Key clinical takeaways:

• Pair the right patient with the right treatment using an understanding of the key clinical studies

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true

X: https://x.com/net_connectinfo

This content is intended for healthcare professionals only.

This podcast is supported by an Independent Education Grant from ITM.

This podcast is developed by cor2ed.com

Published September 2025